We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Research Letter |

Epidemiology and Treatment of Eosinophilic Fasciitis An Analysis of 63 Patients From 3 Tertiary Care Centers

Natalie A. Wright, MD1; Daniel R. Mazori, BA2; Mital Patel, MD1; Joseph F. Merola, MD, MMSC1; Alisa N. Femia, MD2; Ruth Ann Vleugels, MD, MPH1
[+] Author Affiliations
1Department of Dermatology, Brigham and Women’s Hospital, Boston, Massachusetts
2The Ronald O. Perelman Department of Dermatology, New York University Langone Medical Center, New York
JAMA Dermatol. 2016;152(1):97-99. doi:10.1001/jamadermatol.2015.3648.
Text Size: A A A
Published online


This study reports that misdiagnoses, unnecessary procedures, and undertreatment were common among patients with eosinophilic fasciitis, while combination therapy with corticosteroids and methotrexate resulted in higher rates of complete response.

Eosinophilic fasciitis (EF) is a rare fibrosing disorder of the fascia characterized by erythema, edema, and induration of the bilateral extremities. Joint contractures and related functional limitation commonly occur owing to fascial involvement overlying the joints. Hematologic abnormalities, including peripheral eosinophilia and monoclonal gammopathy, may occur. Systemic corticosteroids are considered first-line therapy; however, prolonged treatment is frequently required in patients with EF, and a standardized therapeutic protocol is lacking.1,2 Given the dearth of systematic data guiding treatment, we evaluated the presentation and clinical response of EF in 63 patients at 3 tertiary care centers.

First Page Preview

View Large
First page PDF preview





Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

1 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles
[Adrenal incidentalomas]. Presse Med 2014;43(4 Pt 1):393-400.
Adrenal steroidogenesis and congenital adrenal hyperplasia. Endocrinol Metab Clin North Am 2015;44(2):275-96.